pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
暂无分享,去创建一个
Li Di | Hui Zhang | Iain Gardner | L. Di | M. Varma | A. El‐Kattan | I. Gardner | Charles J. Rotter | Manthena V Varma | Stefanus J Steyn | Paul Nkansah | Charles J Rotter | Carrie Whitney-Pickett | Michael Cram | Katherine S Fenner | Ayman F El-Kattan | K. Fenner | Stefanus J. Steyn | Hui Zhang | Paul Nkansah | Michael Cram | Carrie Whitney-Pickett
[1] Manfred Kansy,et al. High throughput solubility measurement in drug discovery and development. , 2007, Advanced drug delivery reviews.
[2] Marilyn E. Morris,et al. Prediction of Biliary Excretion in Rats and Humans Using Molecular Weight and Quantitative Structure–Pharmacokinetic Relationships , 2009, The AAPS Journal.
[3] Per Artursson,et al. Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA method , 2005 .
[4] Viv Bewick,et al. Statistics review 13: Receiver operating characteristic curves , 2004, Critical care.
[5] Vinod Nair,et al. Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research. , 2004, Current drug metabolism.
[6] F. Russel,et al. Mechanisms and clinical implications of renal drug excretion* , 2001, Drug metabolism reviews.
[7] Jochem Alsenz,et al. Development of a partially automated solubility screening (PASS) assay for early drug development. , 2007, Journal of pharmaceutical sciences.
[8] Hans Lennernäs,et al. Comparison Between Permeability Coefficients in Rat and Human Jejunum , 1996, Pharmaceutical Research.
[9] Sean Ekins,et al. Using Open Source Computational Tools for Predicting Human Metabolic Stability and Additional Absorption, Distribution, Metabolism, Excretion, and Toxicity Properties , 2010, Drug Metabolism and Disposition.
[10] Vinod P. Shah,et al. Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions , 2002, Pharmaceutical Research.
[11] Vinod P. Shah,et al. The Use of BDDCS in Classifying the Permeability of Marketed Drugs , 2008, Pharmaceutical Research.
[12] Tudor I. Oprea,et al. BDDCS Applied to Over 900 Drugs , 2011, The AAPS Journal.
[13] C. Bevan,et al. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. , 2000, Analytical chemistry.
[14] M. Varma,et al. Targeting intestinal transporters for optimizing oral drug absorption. , 2010, Current drug metabolism.
[15] R Scott Obach,et al. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. , 2010, Journal of medicinal chemistry.
[16] Nigel Greene,et al. Physicochemical drug properties associated with in vivo toxicological outcomes: a review , 2009, Expert opinion on drug metabolism & toxicology.
[17] M. Varma,et al. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. , 2005, Journal of pharmaceutical sciences.
[18] S. Wright,et al. The molecular and cellular physiology of basolateral organic anion transport in mammalian renal tubules. , 2003, Biochimica et biophysica acta.
[19] Lawrence X. Yu,et al. The BCS, BDDCS, and Regulatory Guidances , 2011, Pharmaceutical Research.
[20] M. Machida,et al. Biopharmaceutics Classification by High Throughput Solubility Assay and PAMPA , 2004, Drug development and industrial pharmacy.
[21] P. Artursson,et al. Epithelial transport of drugs in cell culture. II: Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.
[22] K. Luthman,et al. Caco-2 monolayers in experimental and theoretical predictions of drug transport. , 2001, Advanced drug delivery reviews.
[23] P. Artursson,et al. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.
[24] Li Di,et al. Development of a new permeability assay using low-efflux MDCKII cells. , 2011, Journal of pharmaceutical sciences.
[25] S. Stegemann,et al. When poor solubility becomes an issue: from early stage to proof of concept. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[26] A. Avdeef,et al. Physicochemical profiling (solubility, permeability and charge state). , 2001, Current topics in medicinal chemistry.
[27] J. Tolan,et al. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.
[28] Lawrence X. Yu,et al. High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. , 2010, Molecular pharmaceutics.
[29] B. Feng,et al. Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state , 2010, Expert opinion on drug metabolism & toxicology.
[30] Alex Avdeef,et al. The rise of PAMPA , 2005, Expert opinion on drug metabolism & toxicology.
[31] Hatsuo Aoki,et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. , 1987 .
[32] Kristina Luthman,et al. Caco-2 monolayers in experimental and theoretical predictions of drug transport1PII of original article: S0169-409X(96)00415-2. The article was originally published in Advanced Drug Delivery Reviews 22 (1996) 67–84.1 , 2001 .
[33] P. Artursson,et al. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.
[34] H Lennernäs,et al. Human intestinal permeability. , 1998, Journal of pharmaceutical sciences.
[35] R. Obach,et al. Physicochemical determinants of human renal clearance. , 2009, Journal of medicinal chemistry.
[36] Pär Matsson,et al. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. , 2011, Journal of medicinal chemistry.
[37] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[38] H Lennernäs,et al. Intestinal permeability and its relevance for absorption and elimination , 2007, Xenobiotica; the fate of foreign compounds in biological systems.
[39] Leslie Z. Benet,et al. Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.
[40] S. Gattani,et al. Solubility Enhancement of Lovastatin by Modified Locust Bean Gum Using Solid Dispersion Techniques , 2008, AAPS PharmSciTech.
[41] Hans Lennernäs,et al. Jejunal Absorption and Metabolism of R/S-Verapamil in Humans , 1998, Pharmaceutical Research.
[42] B. Feng,et al. Physicochemical Property Space of Hepatobiliary Transport and Computational Models for Predicting Rat Biliary Excretion , 2012, Drug Metabolism and Disposition.
[43] J. Denollet,et al. Sensitivity and specificity of observer and self-report questionnaires in major and minor depression following myocardial infarction. , 2001, Psychosomatics.
[44] J. Legendre,et al. Determination of the Aqueous Solubility of Drugs Using a Convenient 96-Well Plate-Based Assay , 2001, Drug development and industrial pharmacy.
[45] Leslie Z Benet,et al. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. , 2008, Advanced drug delivery reviews.